Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Vaccinia Viruses As Vectors For Vaccine Antigens PDF full book. Access full book title Vaccinia Viruses As Vectors For Vaccine Antigens.
| Author | : Gerald V. Quinnan |
| Publisher | : Elsevier Publishing Company |
| Total Pages | : 280 |
| Release | : 1985 |
| Genre | : Medical |
| ISBN | : |
| Author | : Gerald V. Quinnan |
| Publisher | : |
| Total Pages | : 258 |
| Release | : 1985 |
| Genre | : Smallpox |
| ISBN | : |
| Author | : Stuart N. Isaacs |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 402 |
| Release | : 2008-02-03 |
| Genre | : Science |
| ISBN | : 1592597890 |
The Right Book at the Right Time The poxviruses comprise a family of complex DNA viruses that replicate in the cytoplasm of vertebrate or invertebrate cells. Of the eight recognized g- era of vertebrate poxviruses, those belonging to the orthopoxvirus genus have been most intensively studied. This group includes variola virus, the agent of smallpox, as well as cowpox virus and vaccinia virus. Jenner’s original sma- pox vaccine, described in 1798, consisted of live cowpox virus, but vaccinia virus later replaced it (1). There has been speculation as to the origin of v- cinia virus; the most likely idea is that it is a separate species, possibly ori- nally isolated from a horse, and is now extinct or rare in nature (2). Recent genome sequencing studies confirm the distinctness of variola virus, cowpox virus, and vaccinia virus and also their very close genetic relationship, which accounts for the cross protection of smallpox vaccines. The novelty of the smallpox vaccine can be readily appreciated by the time it took, about 80 years, before the next live vaccine against rabies was developed, and another 50 years for the yellow fever vaccine. Moreover, the eradication of smallpox in 1977 stands as a unique medical achievement. Because of its historical role, sma- pox vaccination contributed greatly to present concepts of infectious disease, immunity, and pathogenesis. Less well known, however, are the many other “firsts” for vaccinia virus.
| Author | : Jeffrey Laurence |
| Publisher | : Academic Press |
| Total Pages | : 356 |
| Release | : 2015-11-18 |
| Genre | : Technology & Engineering |
| ISBN | : 0128005521 |
Translating Regenerative Medicine to the Clinic reviews the current methodological tools and experimental approaches used by leading translational researchers, discussing the uses of regenerative medicine for different disease treatment areas, including cardiovascular disease, muscle regeneration, and regeneration of the bone and skin. Pedagogically, the book concentrates on the latest knowledge, laboratory techniques, and experimental approaches used by translational research leaders in this field. It promotes cross-disciplinary communication between the sub-specialties of medicine, but remains unified in theme by emphasizing recent innovations, critical barriers to progress, the new tools that are being used to overcome them, and specific areas of research that require additional study to advance the field as a whole. Volumes in the series include Translating Gene Therapy to the Clinic, Translating Regenerative Medicine to the Clinic, Translating MicroRNAs to the Clinic, Translating Biomarkers to the Clinic, and Translating Epigenetics to the Clinic. Encompasses the latest innovations and tools being used to develop regenerative medicine in the lab and clinic Covers the latest knowledge, laboratory techniques, and experimental approaches used by translational research leaders in this field Contains extensive pedagogical updates aiming to improve the education of translational researchers in this field Provides a transdisciplinary approach that supports cross-fertilization between different sub-specialties of medicine
| Author | : Sara Cohen |
| Publisher | : Springer Science & Business Media |
| Total Pages | : 197 |
| Release | : 2013-06-29 |
| Genre | : Medical |
| ISBN | : 1489913823 |
Vaccination is one of the most efficient and cost effective methods of promoting human health and has been in clinical use for at least 200 years. Nevertheless, infectious diseases continue to constitute a constant threat to the well being of humanity. Common pathogens, once believed to be under control, acquire increased virulence and resistance to drugs, while exotic microorganisms emerged from hidden reservoirs to cause yet incurable diseases in humans. These changes, together with epidemic outbreaks related to political and socio-economic instabilities, increase the needs for the development of new, advanced vaccines. In this volume, devoted to the proceedings of the 39th OHOLO Conference, we present some of the recent strategies for the design and production of novel vaccines. The advent of recombinant DNA technology has stimulated the production of several subunit vaccines. In spite of the obvious advantages to this approach, the limited immuno genicity of many subunit candidates has hindered their development. Strategies to enhance the immunogenicity of subunit vaccines is therefore critical. Several approaches toward this goal, including design of novel adjuvants and delivery systems as well as design of advantageous carriers, are presented here. Among the carriers evaluated here are polypep tides (flagellin, HBV core antigen, J3-galactosidase), attenuated virions (Vaccinia, Sindbis), and nonpathogenic licensed bacteria (Salmonella).
| Author | : Thiru Vanniasinkam |
| Publisher | : Springer Nature |
| Total Pages | : 232 |
| Release | : 2020-11-30 |
| Genre | : Medical |
| ISBN | : 3030519279 |
This highly accessible textbook introduces readers to the development of viral vectors and discusses their application in veterinary vaccinology. It offers comprehensive information on the latest advances in this emerging research field, together with a broad overview of the history of veterinary vaccines and viral vectors. The book also addresses issues concerning funding, translational research and ethics that will impact the future development, manufacture and global use of viral vector-based veterinary vaccines. The book addresses the needs of graduate students and researchers in the fields of Veterinary Medicine, Virology and Immunology.
| Author | : Igor S Lukashevich |
| Publisher | : Springer |
| Total Pages | : 393 |
| Release | : 2014-11-13 |
| Genre | : Medical |
| ISBN | : 3709118182 |
This book presents a detailed overview of the development of new viral vector-based vaccines before discussing two major applications: preventive vaccines for infectious diseases and therapeutic cancer vaccines. Viral vector-based vaccines hold a great potential for development into successful pharmaceutical products and several examples at the advanced pre-clinical or clinical stage are presented. Nevertheless, the most efforts were focused on novel and very innovative technologies for new generation of vector-based vaccines. Furthermore, specific topics such as delivery and adjuvant and protection strategies for cell-mediated-based vaccines are presented. Given its scope, the book is a “must read” for all those involved in vaccine development, both in academia and industrial vaccine development.
| Author | : National Research Council |
| Publisher | : National Academies Press |
| Total Pages | : 118 |
| Release | : 2001-07-11 |
| Genre | : Science |
| ISBN | : 0309075556 |
This report surveys opportunities for future Army applications in biotechnology, including sensors, electronics and computers, materials, logistics, and medical therapeutics, by matching commercial trends and developments with enduring Army requirements. Several biotechnology areas are identified as important for the Army to exploit, either by direct funding of research or by indirect influence of commercial sources, to achieve significant gains in combat effectiveness before 2025.
| Author | : Fred Brown |
| Publisher | : S. Karger AG (Switzerland) |
| Total Pages | : 284 |
| Release | : 1994 |
| Genre | : Medical |
| ISBN | : |
This volume explores the use of recombinant vectors in the development of new vaccines to benefit both human and animal health. Emphasis is placed on bacterial and viral vectors and their applications.
| Author | : Mansoor M. Amiji |
| Publisher | : Elsevier |
| Total Pages | : 548 |
| Release | : 2021-08-27 |
| Genre | : Business & Economics |
| ISBN | : 0128233974 |
Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO
